Haemonetics (NYSE:HAE) Given “Outperform” Rating at Barrington Research

Barrington Research reissued their outperform rating on shares of Haemonetics (NYSE:HAE) in a report published on Monday morning,Benzinga reports. Barrington Research currently has a $93.00 price objective on the medical instruments supplier’s stock.

A number of other analysts have also commented on HAE. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. Needham & Company LLC downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. Raymond James Financial reissued an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a research note on Friday, November 14th. Finally, BTIG Research restated a “buy” rating and set a $88.00 target price on shares of Haemonetics in a research report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.40.

Haemonetics Price Performance

Shares of NYSE HAE opened at $65.83 on Monday. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08. The company’s 50-day moving average price is $78.20 and its 200 day moving average price is $65.32. Haemonetics has a 52 week low of $47.31 and a 52 week high of $87.32. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of 19.25, a PEG ratio of 1.38 and a beta of 0.28.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The business had revenue of $327.32 million for the quarter, compared to analyst estimates of $311.61 million. During the same period in the prior year, the business earned $1.12 earnings per share. The company’s quarterly revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, research analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio purchased a new position in shares of Haemonetics in the 4th quarter worth $986,000. Horizon Investments LLC acquired a new stake in Haemonetics during the fourth quarter worth about $2,398,000. New York State Teachers Retirement System raised its holdings in shares of Haemonetics by 12.1% in the 4th quarter. New York State Teachers Retirement System now owns 55,888 shares of the medical instruments supplier’s stock worth $4,479,000 after purchasing an additional 6,043 shares during the period. Jennison Associates LLC lifted its stake in shares of Haemonetics by 11.9% in the 4th quarter. Jennison Associates LLC now owns 12,103 shares of the medical instruments supplier’s stock valued at $970,000 after purchasing an additional 1,290 shares in the last quarter. Finally, Cardinal Capital Management grew its holdings in shares of Haemonetics by 1.5% during the 4th quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock worth $1,799,000 after purchasing an additional 321 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.